These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 25417182)

  • 1. Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study).
    Fernandez-Plana J; Pericay C; Quintero G; Alonso V; Salud A; Mendez M; Salgado M; Saigi E; Cirera L;
    BMC Cancer; 2014 Nov; 14():865. PubMed ID: 25417182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
    Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
    BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
    Bokemeyer C; Bondarenko I; Makhson A; Hartmann JT; Aparicio J; de Braud F; Donea S; Ludwig H; Schuch G; Stroh C; Loos AH; Zubel A; Koralewski P
    J Clin Oncol; 2009 Feb; 27(5):663-71. PubMed ID: 19114683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
    Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
    Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
    Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.
    Saltz L; Badarinath S; Dakhil S; Bienvenu B; Harker WG; Birchfield G; Tokaz LK; Barrera D; Conkling PR; O'Rourke MA; Richards DA; Reidy D; Solit D; Vakiani E; Capanu M; Scales A; Zhan F; Boehm KA; Asmar L; Cohn A
    Clin Colorectal Cancer; 2012 Jun; 11(2):101-11. PubMed ID: 22055112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
    Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
    Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer.
    Folprecht G; Hamann S; Schütte K; Trarbach T; Stoehlmacher-Williams J; Ehninger G
    BMC Cancer; 2014 Jul; 14():521. PubMed ID: 25038824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial.
    Kasper S; Meiler J; Knipp H; Höhler T; Reimer P; Steinmetz T; Berger W; Linden G; Reis H; Markus P; Paul A; Dechêne A; Schumacher B; Kostbade K; Virchow I; Ting S; Worm K; Schmid KW; Herold T; Wiesweg M; Schuler M; Trarbach T
    Clin Colorectal Cancer; 2020 Dec; 19(4):236-247.e6. PubMed ID: 32737003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.
    Brodowicz T; Ciuleanu TE; Radosavljevic D; Shacham-Shmueli E; Vrbanec D; Plate S; Mrsic-Krmpotic Z; Dank M; Purkalne G; Messinger D; Zielinski CC
    Ann Oncol; 2013 Jul; 24(7):1769-1777. PubMed ID: 23559149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With
    Qin S; Li J; Wang L; Xu J; Cheng Y; Bai Y; Li W; Xu N; Lin LZ; Wu Q; Li Y; Yang J; Pan H; Ouyang X; Qiu W; Wu K; Xiong J; Dai G; Liang H; Hu C; Zhang J; Tao M; Yao Q; Wang J; Chen J; Eggleton SP; Liu T
    J Clin Oncol; 2018 Oct; 36(30):3031-3039. PubMed ID: 30199311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of oxaliplatin in combination with continuous infusion +/- bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial.
    Mosconi S; Cascinu S; Zaniboni A; Catalano V; Giordani P; Beretta GD; Martignoni G; Pancera G; Baldelli AM; Poletti P; Curti C; Labianca R
    Tumori; 2000; 86(6):465-9. PubMed ID: 11218187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
    Wang DS; Ren C; Li SS; Fong WP; Wu XJ; Xiao J; Li BK; Zheng Y; Ding PR; Chen G; Qiu MZ; Wang ZQ; Wang FH; Luo HY; Wang F; Wang XZ; Wang LY; Xie DJ; Chen T; Li LR; Lu ZH; Zhai XH; Liu TS; Yuan Y; Chen JQ; Tan Q; Pan ZZ; Wan DS; Zhang R; Yuan YF; Xu RH; Li YH
    PLoS Med; 2024 May; 21(5):e1004389. PubMed ID: 38728364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer: A meta-analysis.
    Yang YF; Wang GY; He JL; Wu FP; Zhang YN
    Medicine (Baltimore); 2017 Mar; 96(12):e6335. PubMed ID: 28328812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.
    Wasan H; Meade AM; Adams R; Wilson R; Pugh C; Fisher D; Sydes B; Madi A; Sizer B; Lowdell C; Middleton G; Butler R; Kaplan R; Maughan T;
    Lancet Oncol; 2014 May; 15(6):631-9. PubMed ID: 24703531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
    Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
    JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group.
    Pfeiffer P; Sorbye H; Qvortrup C; Karlberg M; Kersten C; Vistisen K; Lindh B; Bjerregaard JK; Glimelius B
    Clin Colorectal Cancer; 2015 Sep; 14(3):170-6. PubMed ID: 25956187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
    Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.
    Ciardiello F; Normanno N; Martinelli E; Troiani T; Pisconti S; Cardone C; Nappi A; Bordonaro AR; Rachiglio M; Lambiase M; Latiano TP; Modoni G; Cordio S; Giuliani F; Biglietto M; Montesarchio V; Barone C; Tonini G; Cinieri S; Febbraro A; Rizzi D; De Vita F; Orditura M; Colucci G; Maiello E;
    Ann Oncol; 2016 Jun; 27(6):1055-1061. PubMed ID: 27002107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.